{"log_id": 228663445668706383, "direction": 0, "words_result_num": 44, "words_result": [{"probability": {"variance": 4e-06, "average": 0.998768, "min": 0.991208}, "location": {"width": 853, "top": 183, "height": 43, "left": 210}, "words": "些患者经常需要输血。上市后也有需要输血的贫血病例报告,更多病例出现在接受利奈唑胺"}, {"probability": {"variance": 0, "average": 0.999663, "min": 0.998898}, "location": {"width": 222, "top": 229, "height": 27, "left": 212}, "words": "治疗超过28天的患者中"}, {"probability": {"variance": 0.00036, "average": 0.993496, "min": 0.889838}, "location": {"width": 807, "top": 251, "height": 41, "left": 256}, "words": "上市后曾报告过铁粒幼细胞贫血病例。在已知其发病时间的患者中,大多数患者的利奈"}, {"probability": {"variance": 3.8e-05, "average": 0.996578, "min": 0.970566}, "location": {"width": 855, "top": 284, "height": 42, "left": 211}, "words": "唑胺疗程超过28天。大多数患者在停用利奈唑胺后,无论是否接受贫血治疗,都可以完全或"}, {"probability": {"variance": 0, "average": 0.999137, "min": 0.998028}, "location": {"width": 88, "top": 331, "height": 26, "left": 211}, "words": "部分康复"}, {"probability": {"variance": 1e-06, "average": 0.999341, "min": 0.996207}, "location": {"width": 802, "top": 386, "height": 39, "left": 251}, "words": "在成年和未成年的狗和大鼠中,曾观察到骨髓抑制、脾脏和肝脏的髓外血细胞生成减少"}, {"probability": {"variance": 0, "average": 0.999597, "min": 0.998058}, "location": {"width": 570, "top": 424, "height": 35, "left": 210}, "words": "胸腺、淋巴结和脾脏的淋巴细胞减少的现象(见【药理毒理】"}, {"probability": {"variance": 1e-06, "average": 0.999283, "min": 0.996575}, "location": {"width": 688, "top": 453, "height": 41, "left": 252}, "words": "在一项导管相关血流感染包括插管部位感染的研究中发现死亡率的不均衡"}, {"probability": {"variance": 5.4e-05, "average": 0.997526, "min": 0.957987}, "location": {"width": 788, "top": 486, "height": 40, "left": 275}, "words": "项利奈唑胺对比万古霉素/双氯西林/苯唑西林治疗血管内导管相关感染的重症患者的"}, {"probability": {"variance": 3.9e-05, "average": 0.996566, "min": 0.968946}, "location": {"width": 843, "top": 519, "height": 41, "left": 209}, "words": "开放性研究中,发现两组死亡率的不均衡[利奈唑胺组死亡率为78/363(21.5%),对照组为"}, {"probability": {"variance": 9e-06, "average": 0.997705, "min": 0.987944}, "location": {"width": 841, "top": 552, "height": 41, "left": 208}, "words": "58/363(16.0%);比值比为1.426,95%可信区间为0.970,2.098]。其因果关系尚未确定"}, {"probability": {"variance": 1.4e-05, "average": 0.9984, "min": 0.978975}, "location": {"width": 851, "top": 584, "height": 41, "left": 212}, "words": "病死率的不均衡主要发生于革兰阴性菌感染、革兰阴性菌和革兰阳性菌混合感染或基线未分"}, {"probability": {"variance": 4e-06, "average": 0.998984, "min": 0.991598}, "location": {"width": 856, "top": 617, "height": 42, "left": 208}, "words": "离到病原菌的利奈唑胺组患者,在单纯革兰阳性菌感染的患者中未发现死亡率的不均衡。影"}, {"probability": {"variance": 4e-06, "average": 0.999069, "min": 0.988495}, "location": {"width": 855, "top": 649, "height": 41, "left": 211}, "words": "响死亡率的主要因素为基线时的革兰阳性菌感染情况。单纯革兰阳性菌感染的患者死亡率相"}, {"probability": {"variance": 0.001439, "average": 0.99083, "min": 0.754746}, "location": {"width": 855, "top": 682, "height": 41, "left": 209}, "words": "似(比值比为0.96;95%置信区间:0.58-1.59),但基线时合并其他病原体或无病原体感染"}, {"probability": {"variance": 0.003333, "average": 0.986719, "min": 0.583981}, "location": {"width": 851, "top": 715, "height": 41, "left": 208}, "words": "时利奈唑胺治疗组的死亡率明显更高(p=0.0162)(比值比为2.48:95%置信区间:1.38-4.46)"}, {"probability": {"variance": 3e-06, "average": 0.999065, "min": 0.990941}, "location": {"width": 863, "top": 747, "height": 41, "left": 209}, "words": "治疗期间以及停用研究药物后7天内死亡率最异常。利奈唑胺治疗组较多患者在研究期间感染"}, {"probability": {"variance": 3e-06, "average": 0.999049, "min": 0.992207}, "location": {"width": 855, "top": 781, "height": 39, "left": 211}, "words": "革兰阴性菌病原体,并死于革兰阴性菌病原体引起的感染和多种微生物感染。因此,治疗复"}, {"probability": {"variance": 1e-05, "average": 0.998896, "min": 0.979959}, "location": {"width": 857, "top": 813, "height": 40, "left": 210}, "words": "杂性皮肤和软组织感染时,只有在无替代治疗方案可用时,利奈唑胺才可应用于已知或疑似"}, {"probability": {"variance": 5e-06, "average": 0.998989, "min": 0.990294}, "location": {"width": 729, "top": 847, "height": 39, "left": 208}, "words": "合并感染革兰阴性菌的患者。在这些情况下,必须同时开始抗革兰阴性菌治疗"}, {"probability": {"variance": 4.9e-05, "average": 0.997227, "min": 0.967698}, "location": {"width": 707, "top": 880, "height": 37, "left": 253}, "words": "利奈唑胺未被批准且不应用于治疗导管相关血流感染或插管部位感染的患者"}, {"probability": {"variance": 2e-06, "average": 0.999116, "min": 0.993998}, "location": {"width": 821, "top": 909, "height": 40, "left": 252}, "words": "利奈唑胺对革兰阴性病原体没有临床疗效,不适用于治疗革兰阴性菌感染。如确诊或疑"}, {"probability": {"variance": 1e-06, "average": 0.999151, "min": 0.995673}, "location": {"width": 873, "top": 941, "height": 42, "left": 208}, "words": "诊合并革兰阴性菌病原体感染,立即开始针对性的抗革兰阴性菌治疗十分重要(见【适应症】"}, {"probability": {"variance": 4.1e-05, "average": 0.994561, "min": 0.980972}, "location": {"width": 147, "top": 984, "height": 28, "left": 210}, "words": "和【用法用量】"}, {"probability": {"variance": 5e-06, "average": 0.998099, "min": 0.993944}, "location": {"width": 251, "top": 1017, "height": 28, "left": 209}, "words": "抗生素相关腹泻和结肠炎"}, {"probability": {"variance": 1.1e-05, "average": 0.997813, "min": 0.98518}, "location": {"width": 827, "top": 1039, "height": 41, "left": 251}, "words": "使用几乎所有抗菌药物(包括利奈唑胺)时都曾有伪膜性结肠炎报告。因此,如果在"}, {"probability": {"variance": 4e-06, "average": 0.99902, "min": 0.988425}, "location": {"width": 869, "top": 1071, "height": 41, "left": 207}, "words": "接受任何抗菌药物后患者出现腹泻,则应考虑伪膜性结肠炎诊断。如果疑诊或确诊患有"}, {"probability": {"variance": 2.2e-05, "average": 0.998012, "min": 0.974719}, "location": {"width": 681, "top": 1105, "height": 41, "left": 206}, "words": "抗生素相关结肠炎,可能需要停用利奈唑胺。应采取适当的处理措施"}, {"probability": {"variance": 4e-06, "average": 0.998861, "min": 0.988064}, "location": {"width": 830, "top": 1136, "height": 41, "left": 249}, "words": "几乎所有抗菌药物(也包括斯沃)使用中都曾有抗生素相关腹泻和结肠炎(包括伪膜性"}, {"probability": {"variance": 3.6e-05, "average": 0.99754, "min": 0.962536}, "location": {"width": 873, "top": 1169, "height": 41, "left": 206}, "words": "结肠炎和难辨梭菌相关腹泻(CDAD))的报道,严重程度可从轻度腹泻到致命性结肠炎。抗"}, {"probability": {"variance": 1e-06, "average": 0.99925, "min": 0.996783}, "location": {"width": 563, "top": 1206, "height": 36, "left": 207}, "words": "菌药物治疗可改变肠道正常菌群,导致难辨梭菌的过度生长"}, {"probability": {"variance": 1e-05, "average": 0.998643, "min": 0.981973}, "location": {"width": 831, "top": 1233, "height": 41, "left": 249}, "words": "难辨梭菌产生A毒素和B毒素,与CDAD的发生有关。难辨梭菌的高量产毒株可导致发"}, {"probability": {"variance": 1.2e-05, "average": 0.999071, "min": 0.978432}, "location": {"width": 873, "top": 1266, "height": 42, "left": 206}, "words": "病率和死亡率升高,这类感染用抗生素治疗困难,有可能需要结肠切除。使用抗生素治疗的"}, {"probability": {"variance": 4e-06, "average": 0.998853, "min": 0.992412}, "location": {"width": 443, "top": 1308, "height": 32, "left": 205}, "words": "患者如果出现腹泻则必须要考虑CDAD的可能"}, {"probability": {"variance": 5e-06, "average": 0.999022, "min": 0.985916}, "location": {"width": 824, "top": 1333, "height": 41, "left": 247}, "words": "据报道,有时CDAD甚至有可能在使用抗菌药物后2月后才出现,故需要详细了解病史"}, {"probability": {"variance": 4e-06, "average": 0.999024, "min": 0.989306}, "location": {"width": 833, "top": 1365, "height": 41, "left": 248}, "words": "因此,如果患者在利奈唑胺治疗期间或之后出现严重腹泻,则应考虑该诊断。如果疑诊"}, {"probability": {"variance": 1e-06, "average": 0.999139, "min": 0.995794}, "location": {"width": 878, "top": 1398, "height": 42, "left": 205}, "words": "或确诊抗生素相关腹泻或CDAD,可能需要停用对难辨梭菌没有直接活性的正在进行的抗菌"}, {"probability": {"variance": 4.3e-05, "average": 0.997522, "min": 0.96063}, "location": {"width": 874, "top": 1431, "height": 42, "left": 206}, "words": "药物治疗(包括利奈唑胺)并立即采取适当的治疗措施。根据临床指征,可适当补液、维持"}, {"probability": {"variance": 2.5e-05, "average": 0.998731, "min": 0.968494}, "location": {"width": 876, "top": 1464, "height": 42, "left": 206}, "words": "电解质平衡和补充蛋白质,给予针对难辨梭菌的抗生素治疗,并进行外科手术评估。在此情"}, {"probability": {"variance": 0.000182, "average": 0.995178, "min": 0.948778}, "location": {"width": 284, "top": 1508, "height": 30, "left": 205}, "words": "况下应禁用抑制肠蠕动的药物"}, {"probability": {"variance": 0, "average": 0.999822, "min": 0.999708}, "location": {"width": 72, "top": 1544, "height": 24, "left": 246}, "words": "低血糖"}, {"probability": {"variance": 9e-06, "average": 0.998221, "min": 0.988466}, "location": {"width": 815, "top": 1563, "height": 41, "left": 245}, "words": "在利奈唑胺上市后的应用中,使用利奈唑胺(可逆的,非选择性的单胺氧化酶抑制剂"}, {"probability": {"variance": 5e-06, "average": 0.997425, "min": 0.993612}, "location": {"width": 154, "top": 1627, "height": 26, "left": 565}, "words": "第13页,共29页"}, {"probability": {"variance": 0.042882, "average": 0.853171, "min": 0.433932}, "location": {"width": 112, "top": 1656, "height": 21, "left": 586}, "words": "辉瑞—机密"}], "language": 3}